Enzyme vs Ripple — how do they compare? Enzyme trades at Rp30,212 (market cap Rp134,13M, Rp104,56M 24h volume), while Ripple trades at Rp20,046 (market cap Rp1.251,82T, Rp21,82T 24h volume). The key difference: Ripple is far larger — about 9332886× Enzyme's market cap, and Ripple's supply is capped (62,5B / 100B XRP (63%)) while Enzyme's keeps growing. Which is the better fit depends on your goals — on Pluang, investors hold Enzyme for 28 Days and Ripple for 68 Days on average.
| MLN | XRP | |
|---|---|---|
Market Cap | Rp134,13M | Rp1.251,82T |
Volume (24h) | Rp104,56M | Rp21,82T |
Circulating Supply | 3,3M MLN | 62,5B / 100B XRP (63%) |
Typical Hold Time | 28 Days | 68 Days |
Signals from Pluang's Aura AI — not financial advice
Enzyme (MLN) currently holds a market capitalization of Rp134.13 million with a circulating supply of 3.3 million tokens. The asset shows moderate market activity with a hold time of 28 days indicating average investor retention. Recent market data suggests stable trading patterns within the decentralized finance ecosystem, though specific price action requires current exchange verification.
Outlook remains cautiously neutral given limited recent protocol updates. Key opportunities include potential DeFi ecosystem growth integration, while risks center on typical crypto volatility and regulatory uncertainty. Investors should monitor on-chain activity and exchange liquidity for clearer directional signals.
XRP trades at Rp20,131, showing neutral technical signals with bearish moving averages. The token has declined significantly from recent highs, with support at Rp19,259 and resistance at Rp20,395. Recent ecosystem developments include Deutsche Bank and Société Générale adopting Ripple's infrastructure, while multiple XRP ETFs hold Rp1 trillion in assets. On-chain metrics suggest potential bottom formation after a 60% drop from 2025 peaks.
Outlook remains cautious with near-term pressure from extended downtrend, but long-term potential exists through institutional adoption. Key risks include regulatory uncertainty and high volatility, while opportunities lie in expanding blockchain utility and potential market recovery. Investors should monitor exchange flows and regulatory developments closely.
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Enzyme is an easy-to-use on-chain asset management system that enables access to digital assets and DeFi from one simple, unified app. It provides a front-to-back execution and order management system, which provides fully automated reporting, risk management, administration, governance and operations.
Read more on MLN →A crypto asset was created by Ripple to be a speedy, less costly and more scalable alternative to both other digital assets and existing monetary payment platforms like SWIFT. It is the native digital asset on the XRP Ledger—an open-source, permissionless and decentralized blockchain technology that can settle transactions in 3-5 seconds.
Read more on XRP →